Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just...

This news story has 3 comments:

Register or Login to rate comments »

fldocmd Comment (1)
 
For all those who think the results are disappointing (Wall St Journal, others, etc) they really don't understand medicine. There was no 40% consensus. Consensus is for earnings estimates, not clinical trials. Comparing a phase II and phase III trial is very difficult to do. The numbers in phase II are always substantially less than phase III. Plus most phase II trials do not show comparable efficacy when larger phase III trials are done. These results are very good, especially in a disease whose front line drugs are far more toxic (methotrexate and Embrel). Side effect profile was essentially no different than placebo. Also oral administration vs subcutaneous injection is preferable. Not to mention nearly a third of patients had already seen previous biologic therapy.
4 Mar, 07:47 AM Reply Like

User 8962031 Comment (1)
 
tonight they will present more data..
we saw data 16 weeks from Esteem 1..they have longer data and a whole other trial..safety profile so much better than biologics..
derms want safe pill..this could be a bridge before biologic use..thus a new..big market..
4 Mar, 08:51 AM Reply Like

jwodbod Comments (2)
 
A long term holder of Celgene. An incorrect interpretation that will be dismissed on Celgenes webcast tonight at 6:00pm.

For those in doubt, visit the Investor Village Board and reference posts by JBWinn, Polo, Grafzepplin and Doolen.
4 Mar, 11:21 AM Reply Like